Demonstrated Anatomic Outcomes in Wet AMD1-4
Sustained absence of retinal fluid was seen in the majority of EYLEA patients at 52 weeks in the Wet AMD pivotal clinical trials.1
- Primary efficacy endpoint in the VIEW trials: Proportion of patients who maintained vision (<15 letters lost) at 52 weeks vs baseline. See primary endpoint results.
EYLEA effectiveness at drying the retina in Wet AMD1,2
Cumulative Incidence of Sustained Absence of Retinal Fluid (VIEW 1 and VIEW 2 integrated post hoc analysis)1,*
Sustained
absence defined
as absent retinal fluid
on ≥2 consecutive
visits
absence defined
as absent retinal fluid
on ≥2 consecutive
visits
Week 52
EYLEA 2 mg
every 4 weeks
EYLEA 2 mg
every 8 weeks†
ranibizumab
every 4 weeks

The analyses of these post hoc endpoints were not multiplicity protected and are descriptive only.
Anatomic measures did not influence treatment decisions in year 1 but were considered in year 25
VIEW 1 and VIEW 2 study designs: Two multicenter, double-masked clinical studies in which patients with Neovascular (Wet) AMD (N=2412; age range: 49-99 years, with a mean of 76 years) were randomized to receive 1) EYLEA 2 mg administered every 8 weeks following 3 initial monthly doses; 2) EYLEA 2 mg administered every 4 weeks; 3) EYLEA 0.5 mg administered every 4 weeks; or 4) ranibizumab 0.5 mg administered every 4 weeks. Protocol-specified visits occurred every 28 (±3) days.
In both studies, the primary efficacy endpoint was the proportion of Wet AMD patients who maintained vision, defined as losing <15 letters of visual acuity at week 52, compared to baseline.
Between week 52 and week 96, all patients received the same study drug and dosage strength as in the first 52 weeks but continued on a regimen where dosing could be extended up to 12 weeks (3 months), based on monthly investigator assessments of prespecified visual and anatomic outcomes. There was no active control comparison group that received a fixed dosing regimen in year 2. Patients were retreated if 1 of the following criteria were met: (1) Loss of 5 letters of visual acuity from best previous score in conjunction with recurrent fluid on time domain–optical coherence tomography (TD-OCT); (2) new or persistent fluid (any new or unchanged cystic retinal edema and/or subretinal fluid) on TD-OCT; (3) new or persistent leakage on fluorescein angiography; (4) new macular hemorrhage; (5) new-onset classic neovascularization; (6) increase in central subfield thickness (CST) of 100 μm (cystic retinal edema and/or subretinal fluid meeting a specific quantitative thickening threshold), as measured by TD-OCT, compared with lowest previous value; (7) time lapse of 12 weeks since previous injection.3
Efficacy endpoints evaluated after week 52 were exploratory and included the proportion of patients maintaining visual acuity, the mean change in BCVA from baseline, and the proportion of patients gaining 15 letters or more. The results of these exploratory endpoints require cautious interpretation and could represent chance findings, as a multiplicity adjustment has not been applied.
- Full analysis set.
- †Following 3 initial monthly doses.
In a post hoc analysis, the majority of Wet AMD patients treated with EYLEA had a dry retina at Week 52.2
Proportion of Patients With a Dry Retina at 52 Weeks (post hoc endpoint)2

The analyses of these post hoc endpoints were not multiplicity protected and are descriptive only.
Anatomic measures did not influence treatment decisions in year 1 but were considered in year 25
Primary efficacy endpoint in the VIEW clinical trials: Proportion of Wet AMD patients who maintained vision (<15 letters lost) at 52 weeks vs baseline. See primary endpoint results.
- *Following 3 initial monthly doses.
Proportion of Wet AMD Patients Treated Only With Every–12–Week Dosing in Year 2 Who Were Without Retinal Fluid at Week 96 (post hoc subgroup analysis) (VIEW 1 and VIEW 2 integrated efficacy results)3,*


The analyses of these post hoc endpoints were not multiplicity protected and are descriptive only.
Anatomic measures did not influence treatment decisions in year 1 but were considered in year 25
Primary efficacy endpoint in the VIEW clinical trials: Proportion of Wet AMD patients who maintained vision (<15 letters lost) at 52 weeks vs baseline. See primary endpoint results.
- Full analysis set; observed cases.
- †Following 3 initial monthly doses.
Prespecified Analyses of Central Retinal Thickness in Wet AMD
EYLEA decreased mean central retinal thickness by ≈130 μm to 150 μm regardless of dosing schedule across VIEW 1 and VIEW 2 clinical trials.3,4
Mean Change in Central Retinal Thickness, as Measured by OCT,* Over 96 Weeks (prespecified exploratory analysis) (VIEW 1 and VIEW 2 integrated efficacy results)4,†


The results of these exploratory endpoints require cautious interpretation and could represent chance findings, as a multiplicity adjustment has not been applied.
Anatomic measures did not influence treatment decisions in year 1 but were considered in year 25
Primary efficacy endpoint in the VIEW clinical trials: Proportion of Wet AMD patients who maintained vision (<15 letters lost) at 52 weeks vs baseline. See primary endpoint results.
- Optical coherence tomography.
- †Last observation carried forward; full analysis set. VIEW 1: OCTs mandatory at baseline and weeks 4,12, 24, 36, 52, and every 4 weeks thereafter through week 96; VIEW 2: OCTs mandatory at all visits.
- ‡Following 3 initial monthly doses.
Mean Reductions in Central Retinal Thickness, as Measured by TD–OCT,* in Eyes Treated Only With Every–12–Week Dosing in Year 2 (post hoc subgroup analysis) (VIEW 1 and VIEW 2 integrated efficacy results)3,†


The analyses of these post hoc endpoints were not multiplicity protected and are descriptive only.
Anatomic measures did not influence treatment decisions in year 1 but were considered in year 25
Primary efficacy endpoint in the VIEW clinical trials: Proportion of Wet AMD patients who maintained vision (<15 letters lost) at 52 weeks vs baseline. See primary endpoint results.
- Time domain–optical coherence tomography.
- †Last observation carried forward; full analysis set.
- ‡Following 3 initial monthly doses.

Get information about navigating the
reimbursement process. Find enrollment forms, learn about PA assistance, and more.

Find complete product support—
guiding you through
orders, returns, and more.